SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Obesity
Beyond MariTide: Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech into the future.
September 10, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Rough road to money stock illustration
Mergers & Acquisitions
Hectic Markets, Emotions Lead Biotechs To Tack On CVRs
Contingent value rights are rising in a down market, helping to close the gap between buyer and seller expectations in biotech transactions.
September 10, 2025
 · 
6 min read
 · 
Annalee Armstrong
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Government
Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform
In a livestreamed meeting Tuesday afternoon, Health Secretary Robert F. Kennedy Jr. drew a dark portrait of the state of America’s health while addressing the MAHA Commission’s most recent report, which includes plans to research potential links between vaccines and rising rates of chronic disease.
September 9, 2025
 · 
3 min read
 · 
Heather McKenzie
Money coins flow from tap. Cash flow with tiny businessmen open the tap symbol illustration
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year.
September 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
FDA Turns Away Ultra-Rare Disease Therapy
After receiving a complete response letter for its pyruvate dehydrogenase complex deficiency candidate, Saol Therapeutics anticipates it will need “several years” and “significant financial resources” to address the FDA’s concerns.
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
Truist Securities called pumitamig’s data on Monday “very reassuring,” given the consistency between its performance in Chinese and global patient populations.
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Marburg, Germany - July 6, 2013: Marburg Office of Swiss multinational company Novartis AG
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage art of a hand touching a cat. Modern and creative design with surreal style. Perfect for use in posters, editorial design, social media, digital art, and contemporary art projects
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.”
September 9, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA recently approved BESREMi for the treatment of
Manufacturing
As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof Point
Ori Biotech’s CEO said the prioritization of review by FDA, coupled to the impact of the technology, could shave up to three years off development timelines.
September 9, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS